Adverse pregnancy conditions among privately-insured women with and without congenital heart defects
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Adverse pregnancy conditions among privately-insured women with and without congenital heart defects

Filetype[PDF-1.93 MB]


English

Details:

  • Alternative Title:
    Circ Cardiovasc Qual Outcomes
  • Personal Author:
  • Description:
    Background

    In women with congenital heart defects (CHD), changes in blood volume, heart rate, respiration, and edema during pregnancy may lead to increased risk of adverse outcomes and conditions. The American Heart Association (AHA) recommends providers of pregnant women with CHD assess cardiac health and discuss risks and benefits of cardiac-related medications. We described receipt of AHA-recommended cardiac evaluations, filled potentially teratogenic or fetotoxic (Food and Drug Administration pregnancy category D/X) cardiac-related prescriptions, and adverse conditions among pregnant women with CHD compared to those without CHD.

    Methods and Results

    Using 2007–2014 U.S. healthcare claims data, we ascertained a retrospective cohort of women with and without CHD ages 15–44 years with private insurance covering prescriptions during pregnancy. CHD was defined as ≥1 inpatient code or ≥2 outpatient CHD diagnosis codes >30 days apart documented outside of pregnancy and categorized as severe or non-severe. Log-linear regression, accounting for multiple pregnancies per woman, generated adjusted prevalence ratios (aPR) for associations between presence/severity of CHD and stillbirth, preterm birth, and adverse conditions from last menstrual period (LMP) to 90 days postpartum. We identified 2,056 women with CHD (2,334 pregnancies) and 1,374,982 women without (1,524,077 pregnancies). During LMP to 90 days postpartum, 56% of women with CHD had comprehensive echocardiograms and, during pregnancy, 4% filled potentially teratogenic or fetotoxic cardiac-related prescriptions. Women with CHD, compared to those without, experienced more adverse conditions overall (aPR=1.9, 95% CI:1.7–2.1) and, specifically, obstetric (aPR=1.3, 95% CI:1.2–1.4) and cardiac conditions (aPR=10.2, 95% CI:9.1–11.4); stillbirth (aPR=1.6, 95% CI:1.1–2.4); and preterm delivery (aPR=1.6, 95% CI:1.4–1.8). More women with severe CHD, compared to non-severe, experienced adverse conditions overall (aPR=1.5, 95% CI:1.2–1.9).

    Conclusions

    Women with CHD have elevated prevalence of adverse cardiac and obstetric conditions during pregnancy, 4 in 100 used potentially teratogenic or fetotoxic medications, and only half received an AHA-recommended comprehensive echocardiogram.

  • Subjects:
  • Source:
  • Pubmed ID:
    32506927
  • Pubmed Central ID:
    PMC7372719
  • Document Type:
  • Funding:
  • Volume:
    13
  • Issue:
    6
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov